
Verona Pharma to share phase 3 COPD trial data at ATS 2024
Betsy Goodfellow | May 2, 2024 | News story | Medical Communications | COPD, Cardiology, clinical trial, verona pharma
Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including additional analysis from its phase 3 ENHANCE studies which assessed ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD).
According to the press release, ‘pooled analysis demonstrating reductions in the rate and risk of exacerbations with ensifentrine will be presented as part of the ‘Late Breaking Mini Symposium’ designed to highlight new breakthroughs’.
Ensifentrine is a novel selective dual inhibitor of enzymes phosphodiesterase 3 and phosphodiesterase 4 (PDE3 and PDE4) which combines bronchodilator and non-steroidal anti-inflammatory effects into one molecule.
The drug is currently under review by the US Food and Drug Administration (FDA). If approved, the drug could become the first novel inhaled mechanism for COPD maintenance treatment in over two decades.
Frank Sciurba MD, associate professor of medicine at the University of Pittsburgh School of Medicine, US, commented: “These pooled analyses from the ENHANCE studies provide further evidence of ensifentrine’s potential to become an important therapy in a broad population of COPD patients. The substantial reduction in exacerbation rate and risk with ensifentrine is particularly exciting for patients and physicians.”
Betsy Goodfellow
Related Content

AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a …

SMC accepts atogepant for acute migraine treatment in Scotland
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the …

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …






